A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

United States

The University of Arizona Cancer Center - North Campus, Tucson, Arizona

UCLA Clark Urology Center, Los Angeles, California

University of California San Francisco, San Francisco, California

Bioresearch Partner, Aventura, Florida

Bioresearch Partner, Hialeah, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

New Mexico Oncology Hematology Consultants, Ltd., Albuquerque, New Mexico

UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Duke University Medical Center - Duke Cancer Center, Durham, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Carolina Urologic Research Center, Myrtle Beach, South Carolina

University of Texas Southwestern Medical Center, Dallas, Texas

Oncology Consultants, Houston, Texas

University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington